New combo therapy aims to boost radioactive iodine success in young thyroid cancer patients

NCT ID NCT06458036

First seen Jan 06, 2026 · Last updated May 05, 2026 · Updated 13 times

Summary

This study tests whether giving a drug called selpercatinib for 6 months before radioactive iodine therapy can improve treatment outcomes in children, teens, and young adults (ages 2-25) with a specific genetic form of thyroid cancer (RET fusion). The goal is to make the cancer absorb more radioactive iodine, potentially leading to better responses and fewer side effects. About 13 participants will be enrolled at the Children's Hospital of Philadelphia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact

  • Seattle Children's Hospital

    NOT_YET_RECRUITING

    Seattle, Washington, 98105, United States

    Contact

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact

Conditions

Explore the condition pages connected to this study.